By Oliver Griffin

GlaxoSmithKline PLC (GSK.LN) said Tuesday that new clinical data from a phase 3 trial has demonstrated high efficacy of Fluarix Tetra, an influenza vaccine for young children.

GSK said that Fluarix Tetra prevented influenza types A and B--acute, highly contagious, respiratory diseases caused by influenza viruses which are mainly spread through respiratory droplets.

The company said Fluarix Tetra demonstrated 63.2% vaccine efficacy against laboratory-confirmed moderate-to-severe influenza, and efficacy of 49.8% against influenza of any severity in children aged six months to 35 months.

In culture-confirmed influenza, Fluarix Tetra demonstrated vaccine efficacy of 77.6% in moderate-to-severe influenza, and efficacy of 60.1% against influenza of any severity, GSK said.

Write to Oliver Griffin at oliver.griffin@dowjones.com

(END) Dow Jones Newswires

March 06, 2018 06:49 ET (11:49 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Gsk Charts.